The disease burden of respiratory syncytial virus in older adults.

Journal

Current opinion in infectious diseases

ISSN: 1473-6527

Titre abrégé: Curr Opin Infect Dis

Pays: United States

ID NLM: 8809878

Informations de publication

Date de publication:
11 Jan 2024

Historique:

medline: 10 1 2024

pubmed: 10 1 2024

entrez: 10 1 2024

Statut: aheadofprint

Résumé

To highlight the respiratory syncytial virus (RSV) disease burden and the current developments and challenges in RSV prevention for older adults ≥60 years through analysis of RSV epidemiology and the effectiveness of emerging vaccines. In industrialized countries, RSV incidence rates and hospitalization rates among older adults are estimated to be 600.7 cases per 100 000 person-years and 157 hospitalizations per 100 000 person-years, respectively. Yet, accurately determining RSV morbidity and mortality in older adults is challenging, thus resulting in substantially under-estimating the disease burden. The in-hospital fatality rates vary substantially with age and geographies, and can be as high as 9.1% in developing countries. Two promising RSV vaccines for the elderly have been approved, demonstrating efficacies of up to 94.1%, signifying considerable advancement in RSV prevention. However, concerns over potential side effects remain. RSV is associated with a significant burden in older adults. While the landscape of RSV prevention in older adults is promising with the licensure of vaccines from two companies, current trial data underscore the need for additional studies. Addressing the real-world effectiveness of these vaccines, understanding potential rare side effects, and ensuring broad inclusivity in future trials are crucial steps to maximize their potential benefits.

Identifiants

DOI: 10.1097/QCO.0000000000001000 PMID: 38197402

pubmed: 38197402

doi: 10.1097/QCO.0000000000001000

pii: 00001432-990000000-00132

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66:281–290.

Smith EC, Popa A, Chang A, et al. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J 2009; 276:7217–7227.

Falsey AR, Walsh EE. Respiratory syncytial virus prefusion F vaccine. Cell 2023; 186:3137–13137. e1.

CDC. RSV transmission 2023 [updated 2023/09/25]. Available at: https://www.cdc.gov/rsv/about/transmission.html.

Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Global Health 2019; 7:e1031–e1045.

Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399:2047–2064.

Cong B, Dighero I, Zhang T, et al. Understanding the age spectrum of respiratory syncytial virus associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC Med 2023; 21:224.

Li Y, Kulkarni D, Begier E, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther 2023; 12:1137–1149.

Onwuchekwa C, Moreo LM, Menon S, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis 2023; 228:173–184.

Ramirez J, Carrico R, Wilde A, et al. Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR. Infect Dis Ther 2023; 12:1593–1603.

Nguyen-Van-Tam JS, O’Leary M, Martin ET, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev 2022; 31:220105.

Shi T, Vennard S, Jasiewicz F, et al. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis 2022; 226: (Suppl 1): S17–S21.

Havers FP, Whitaker M, Melgar M, et al. Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus – RSV-NET, 12 States, July 2022–June 2023. Am J Transplant 2023; 23:2000–2007.

Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388:595–608.

Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465–1477.

Korsten K, Adriaenssens N, Coenen S, et al. Contact with young children increases the risk of respiratory infection in older adults in Europe—the RESCEU Study. J Infect Dis 2022; 226: (Suppl 1): S79–S86.

Staadegaard L, Caini S, Wangchuk S, et al. Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. Influenza Other Respir Viruses 2021; 15:732–741.

Deng S, Guo L, Cohen C, et al. Impact of subgroup distribution on seasonality of human respiratory syncytial virus: A global systematic analysis. J Infect Dis 2023; doi: 10.1093/infdis/jiad192.

doi: 10.1093/infdis/jiad192

Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390:946–958.

Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749–1759.

Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014; 209:1873–1881.

Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J 2021; 57:2002688.

Kurai D, Natori M, Yamada M, et al. Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: a prospective cohort study in Japan. Influenza Other Respir Viruses 2022; 16:298–307.

Nicholson KG, Kent J, Hammersley V, et al. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. Br Med J 1997; 315:1060–1064.

Smithgall M, Maykowski P, Zachariah P, et al. Epidemiology, clinical features, and resource utilization associated with respiratory syncytial virus in the community and hospital. Influenza Other Respir Viruses 2020; 14:247–256.

Zuurbier RP, Korsten K, Verheij TJM, et al. Performance assessment of a rapid molecular respiratory syncytial virus point-of-care test: a prospective community study in older adults. J Infect Dis 2022; 226: (Suppl 1): S63–S70.

Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis 2020; 222: (Suppl 7): S577–S583.

Juhn YJ, Wi CI, Takahashi PY, et al. Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 pandemic. JAMA Network Open 2023; 6:e2250634.

Ang L, Mak TM, Cui L, et al. Characterisation of respiratory syncytial virus activity in children and adults presenting with acute respiratory illness at primary care clinics in Singapore, 2014–2018. Influenza Other Respir Viruses 2020; 14:412–419.

Belongia EA, King JP, Kieke BA, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis 2018; 5:ofy316 1–10.

Bruyndonckx R, Coenen S, Butler C, et al. Respiratory syncytial virus and influenza virus infection in adult primary care patients: Association of age with prevalence, diagnostic features and illness course. Int J Infect Dis 2020; 95:384–390.

Galli C, Pellegrinelli L, Bubba L, et al. When the COVID-19 pandemic surges during influenza season: Lessons learnt from the sentinel laboratory-based surveillance of influenza-like illness in Lombardy during the 2019–2020 season. Viruses 2021; 13:695.

Meerhoff TJ, Fleming D, Smith A, et al. Surveillance recommendations based on an exploratory analysis of respiratory syncytial virus reports derived from the European Influenza Surveillance System. BMC Infect Dis 2006; 6:1–7.

Pellegrinelli L, Galli C, Bubba L, et al. Respiratory syncytial virus in influenza-like illness cases: epidemiology and molecular analyses of four consecutive winter seasons (2014–2015/2017–2018) in Lombardy (northern Italy). J Med Virol 2020; 92:2999–3006.

Varghese BM, Dent E, Chilver M, et al. Epidemiology of viral respiratory infections in Australian working-age adults (20–64 years): 2010–2013. Epidemiol Infect 2018; 146:619–626.

Zambon MC, Stockton JD, Clewley JP, et al. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 2001; 358:1410–1416.

Jackson ML, Scott E, Kuypers J, et al. Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older-Washington State, 2011/2012–2015/2016. J Infect Dis 2021; 223:147–156.

McClure DL, Kieke BA, Sundaram ME, et al. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults ≥50 years old. PLoS One 2014; 9:e102586.

Savic M, Penders Y, Shi T, et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza Other Respir Viruses 2018; 17:e13031 1–10.

Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, et al. Estimation of the number of RSV-associated hospitalisations in adults in the European Union. J Infect Dis 2023; 228:1539–1548.

Moyes J, Walaza S, Pretorius M, et al. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect 2017; 75:346–355.

Falsey AR, Walsh EE, Esser MT, et al. Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. J Med Virol 2019; 91:65–71.

Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis 2020; 222:1298–1310.

Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010; 50:747–751.

Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 2015; 15:443.

Hansen CL, Chaves SS, Demont C, et al. Mortality associated with influenza and respiratory syncytial virus in the US, 1999–2018. JAMA Network Open 2022; 5:e220527.

Mao Z, Li X, Korsten K, et al. Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in european community-dwelling older adults. J Infect Dis 2022; 226: (Suppl 1): S87–S94.

Choi Y, Hill-Ricciuti A, Branche AR, et al. Cost determinants among adults hospitalized with respiratory syncytial virus in the United States. Influenza Other Respir Viruses 2022; 16:151–158.

Ackerson B, An J, Sy LS, et al. Cost of hospitalization associated with respiratory syncytial virus infection versus influenza infection in hospitalized older adults. J Infect Dis 2020; 222:962–966.

Pastula ST, Hackett J, Coalson J, et al. Hospitalizations for respiratory syncytial virus among adults in the United States, 1997–2012. Open Forum Infect Dis 2017; 4:ofw270.

Chen L, Han X, Li Y, et al. Comparison of clinical characteristics and outcomes between respiratory syncytial virus and influenza-related pneumonia in China from 2013 to 2019. Eur J Clin Microbiol Infect Dis 2021; 40:1633–1643.

Prasad N, Newbern EC, Trenholme AA, et al. The health and economic burden of respiratory syncytial virus associated hospitalizations in adults. PLoS One 2020; 15:e0234235.

Yoon JG, Noh JY, Choi WS, et al. Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults. Sci Rep 2020; 10:12106.

Rafferty E, Paulden M, Buchan SA, et al. Evaluating the individual healthcare costs and burden of disease associated with RSV across age groups. Pharmacoeconomics 2022; 40:633–645.

Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices – United States, 2023. MMWR Morbid Mortal Weekly Rep 2023; 72:793–801.

Moderna Inc. Moderna announces global regulatory submissions for its respiratory syncytial virus (RSV) vaccine, MRNA-1345. ACCESSWIRE News Room. 2023.

Widmer K, Zhu Y, Williams JV, et al. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis 2012; 206:56–62.

Widmer K, Griffin MR, Zhu Y, et al. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014; 8:347–352.